Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

Similar Outcomes In Babies Born Following ICSI Or IVF
Analysis of the longest running ICSI programme in the United States has found reassuring evidence that babies born from frozen embryos fertilised via ICSI (intracytoplasmic sperm injection) do just as well as those born from frozen embryos fertilised via standard IVF treatment.
generic viagra online
Yale Discovery May Open Door To Drug That Cuts Appetite And Boosts Energy
In a major advance in obesity and diabetes research, Yale School of Medicine scientists have found that reducing levels of a key enzyme in the brain decreased appetites and increased energy levels.
News of the day
Obama Pitches Health Reform To Public And Congress, Argues Inaction Is Unacceptable
"With many Americans growing anxious about his plans to overhaul the nation"s healthcare system, President Obama on Wednesday sought to lay out in personal terms how they stand to gain from the legislation that he has made one of the top goals of his presidency," the Los Angeles Times reports. He used the speech to reach out to people who already have insurance, arguing that skyrocketing costs must be slowed and that inaction would hobble businesses and families alike. In making the case for health reform to the American public, however, Obama described specific policy ideas and "relied on jargon that Washington insiders embrace but that might leave the typical television viewer mystified" (Nicholas, Parsons and Levey, 7/23).
Health Insurance

BioAlliance Pharma Obtains European Approval For Loramyc(R) Tablet Embossing And Extension Of Its Shelf Life To 36 Months

BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on therapy and supportive care in cancer and AIDS, announced Europe-wide approval for embossing its Loramyc® mucoadhesive buccal tablet, developed for the treatment of oropharyngeal candidiasis. The embossing process has thus been approved under the Mutual Recognition Procedure; it was first required for the US market, where BioAlliance Pharma submitted a new drug application for Loramyc® to the Food and Drug Administration (FDA) in June 2009. BioAlliance Pharma will be able to harmonize Loramyc® production within those two key markets. BioAlliance Pharma also received European approval for extension of Loramyc®"s shelf life from 18 to 36 months. These two key industrial parameters are complementary assets for Loramyc® and will help optimizing manufacturing, storage and distribution costs. BioAlliance Pharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009